Its early clinical study (NCT02500914) included patients with refractory SCLC/large cell neuroendocrine carcinoma (n = 35) treated with SC-002 and showed an ORR of 14% (5/35) and an ORR of 11.8% in patients screened by immunohistochemistry for DLL3 expression. This evidence concerns the gene DLL3 and small cell lung carcinoma.